Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
MELBOURNE, Australia and NEW YORK, Dec. 06, 2023 -- Incannex Healthcare Inc. , , a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine...
Source: marketscreener.com